Formation of platelet microaggregates correlates with adverse clinical outcome in patients with coronary artery disease

Summary

Platelet activation plays a pivotal role in the pathogenesis of acute coronary syndromes. Laser-light scattering in a platelet aggregometer was used to evaluate aggregate size and number quantitatively. Small platelet aggregates ultimately develop into medium and then large platelet aggregates. Thus the measurement of small platelet aggregates is important in the evaluation of thrombus formation.

We examined the relationship between small platelet aggregates and the occurrence of subsequent cardiovascular events. We followed-up 204 patients (149 men and 55 women, mean age 68 ± 9 years) with coronary artery disease (CAD) for 48 months. Blood sampling to determine platelet aggregation was performed on the day of hospital discharge.

The degree of small platelet aggregates [relative risk 4.34, 95% confidence interval (1.62-11.7), p = 0.004] and low left-ventricular ejection fraction [relative risk 2.88, 95% confidence interval (1.23-6.73), p = 0.015] were independent predictors of the occurrence of cardiovascular events in multivariate Cox hazard analysis. In Kaplan-Meier analysis, the degree of small platelet aggregates correlated with the probability of cardiovascular event occurrence.

In patients with CAD, an increase in small platelet aggregates is closely correlated with the future occurrence of cardiovascular events

Keywords

Cardiovascular events - coronary artery disease - coronary risk factor - platelet aggregation

• References

• 1 Ault KA, Cannon CP, Mitchell J. et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 33: 634-9.
• 2 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-9.
• 3 Ries H, Braun G, Brehm G, Hiller E. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Pathol 1986; 85: 50-6.
• 4 Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994; 218: 284-94.
• 5 Satoh K, Ozaki Y, Qi R. et al. Factors that affect the size of platelet aggregates in epinephrine-induced activation: A study using the particle counting method based on light scattering. Thromb Res 1996; 81: 515-23.
• 6 Eto K, Takeshita S, Ochiai M, Ozaki Y, Sato T, Isshiki T. Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser scattering to assess platelet aggregability. Cardiovasc Res 1998; 40: 223-9.
• 7 Miyamoto S, Ogawa H, Soejima H. et al. Increased rate of formation of small-sized platelet aggregates in patients with acute coronary syndromes. Jpn Circ J 2000; 64: 647-52.
• 8 Trip DM, Cats MV, van Capelle LJF, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-54.
• 9 Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-7.
• 10 Breddin HK, Lippold R, Bittner M, Kirchmaier CM, Krzywanek HJ, Michaelis J. Spontaneous platelet aggregation as a predictive risk factor for vascular occlusion in healthy volunteers? Results of the HAPARG study. Atherosclerosis 1999; 144: 211-9.
• 11 Mock MB, Ringqvist I, Fisher LD. et al. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1982; 66: 562-8.
• 12 Califf RM, Mark DB, Harrell Jr FE. et al. Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. J Am Coll Cardiol 1988; 11: 20-6.
• 13 Sakamoto T, Ogawa H, Kawano H. et al. Rapid change of platelet aggregability in acute hyperglycemia detection by a novel laser-light scattering method. Thromb Haemost 2000; 83: 475-9.
• 14 Miyamoto S, Ogawa H, Soejima H. et al. Formation of platelet aggregates after attacks with coronary spastic angina pectoris. Am J Cardiol 2000; 85: 494-7.
• 15 Tohgi H, Takahashi H, Watanabe K, Kuki H, Shirasawa Y. Development of large platelet aggregates from small aggregates as determined by laser-light scattering: Effect of aggregant concentration and antiplatelet medication. Thromb Haemost 1996; 75: 838-43.
• 16 The expert committee. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
• 17 Shukla SD, Paul A, Klachko DM. Hypersensitivity of diabetic human platelets to platelet activating factor. Thromb Res 1992; 66: 239-46.
• 18 Davi G, Gresele P, Violi F. et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
• 19 Hawkins R. Smoking, platelets and thrombosis. Nature 1972; 236: 450-2.
• 20 Kabbani SS, Watkins MW, Ashikaga T. et al. Platelet reactivity characterized prospectively. A determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 181-6.
• 21 Kajiwara I, Ogawa H, Soejima H. et al. The prognostic value of small-sized platelet aggregates in unstable angina: detection by a novel laser-light scattering method. Thromb Res 2001; 101: 109-18.
• 22 Holmes Jr DR, Detre KM, Williams DO. et al. Long-term outcome of patients with depressed left ventricular function undergoing percutaneous transluminal coronary angioplasty. The NHLBI PTCA Registry. Circulation 1993; 87: 21-9.
• 23 Yusuf S, Zucker D, Peduzzi P. et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-70.
• 24 Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993; 87: 659-75.
• 25 Antiplatelet trialists’ collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320-31.
• 26 Yasue H, Ogawa H, Tanaka H. et al. Effects of aspirin and trapidil on cardiovascular events after acute myocardial infarction. Am J Cardiol 1999; 83: 1308-13.
• 27 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets: I: acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-9.